ArticleInvestigational new drugs2025

Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.

Dwight H Owen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.